

09/20/99  
PTO

PTO/SB/05 (4/98)

Approved for use through 09/30/2000. OMB 0651-0032  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCEPlease type a plus sign (+) inside this box → 

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

# UTILITY PATENT APPLICATION TRANSMITTAL

(Only for new nonprovisional applications under 37 C.F.R. § 1.53(b))

Attorney Docket No. OMRF 152 DIV(3)

First Inventor or Application Identifier Keiji Fukudome

Title Cloning and Regulation of an Endothelial Cell Protein  
C/Activated Protein C Receptor

Express Mail Label No. EL 273 004 882 US

**APPLICATION ELEMENTS**

See MPEP chapter 600 concerning utility patent application contents.

1.  \* Fee Transmittal Form (e.g., PTO/SB/17)  
(Submit an original and a duplicate for fee processing)

2.  Specification [Total Pages 45]  
(preferred arrangement set forth below)
 

- Descriptive title of the Invention
- Cross References to Related Applications
- Statement Regarding Fed sponsored R & D
- Reference to Microfiche Appendix
- Background of the Invention
- Brief Summary of the Invention
- Brief Description of the Drawings (if filed)
- Detailed Description
- Claim(s)
- Abstract of the Disclosure

3.  Drawing(s) (35 U.S.C. 113) [Total Sheets 10]

4. Oath or Declaration [Total Pages 55]
 

- a.  Newly executed (original or copy)
- b.  Copy from a prior application (37 C.F.R. § 1.63(d))  
(for continuation/divisional with Box 16 completed)
  - i.  DELETION OF INVENTOR(S)  
Signed statement attached deleting inventor(s) named in the prior application, see 37 C.F.R. §§ 1.63(d)(2) and 1.33(b).

**\*NOTE FOR ITEMS 1 & 13: IN ORDER TO BE ENTITLED TO PAY SMALL ENTITY FEES, A SMALL ENTITY STATEMENT IS REQUIRED (37 C.F.R. § 1.27), EXCEPT IF ONE FILED IN A PRIOR APPLICATION IS RELIED UPON (37 C.F.R. § 1.28).**

**ADDRESS TO:** Assistant Commissioner for Patents  
Box Patent Application  
Washington, DC 20231

5.  Microfiche Computer Program (Appendix)

6. Nucleotide and/or Amino Acid Sequence Submission  
(if applicable, all necessary)
 

- a.  Computer Readable Copy
- b.  Paper Copy (identical to computer copy)
- c.  Statement verifying identity of above copies

**ACCOMPANYING APPLICATION PARTS**

7.  Assignment Papers (cover sheet & document(s))

8.  37 C.F.R. § 3.73(b) Statement  Power of (when there is an assignee)  Attorney

9.  English Translation Document (if applicable)

10.  Information Disclosure Statement (IDS)/PTO-1449  Copies of IDS Citations

11.  Preliminary Amendment

12.  Return Receipt Postcard (MPEP 503)  
(Should be specifically itemized)
 

- \* Small Entity Statement(s)  Statement filed in prior application, (PTO/SB/09-12)  Status still proper and desired
- 13.  Certified Copy of Priority Document(s)  
(if foreign priority is claimed)
- 14.  Other: .....
- 15.  Other: .....

16. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in a preliminary amendment:

 Continuation  Divisional  Continuation-in-part (CIP) of prior application No: 09,182,616

Prior application information: Examiner S. Gucker

Group / Art Unit: 1636

For CONTINUATION or DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 4b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts.

**17. CORRESPONDENCE ADDRESS**

<input type="checkbox"/> Customer Number or Bar Code Label	(Insert Customer No. or Attach bar code label here)				or <input checked="" type="checkbox"/> Correspondence address below
Name	Patrea L. Pabst				
	Arnall Golden & Gregory, LLP				
Address	2800 One Atlantic Center				
	1201 West Peachtree Street				
City	Atlanta	State	GA	Zip Code	30309-3450
Country	United States	Telephone	(404) 873-8794	Fax	(404) 873-8795

Name (Print/Type)	Patrea L. Pabst	Registration No. (Attorney/Agent)	31,284
Signature		Date	08/20/99

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Box Patent Application, Washington, DC 20231.

JC678 U.S. PTO  
09/37821

08/20/99

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicants: Kenji Fukudome and Charles T. Esmon

Serial No.: Divisional of 09/182,616

Express Mail Label No.:  
EL 273 004 882 US

Filed: August 20, 1999

For: *CLONING AND REGULATION OF AN ENDOTHELIAL CELL  
PROTEIN C/ACTIVATED PROTEIN C RECEPTOR*

Box Patent Applications  
Assistant Commissioner for Patents  
Washington, D.C. 20231

**PRELIMINARY AMENDMENT**

Sir:

Prior to examination of this application, please amend the specification and claims as follows. An Information Disclosure Statement is also enclosed.

**In the Specification**

Page 1, delete the priority information and insert in place thereof, --This application is a divisional of U.S. Serial No. 09/182,616, filed on October 29, 1998, which is a divisional of U.S. Serial No. 08/878, 283, filed on June 18, 1997, now U.S. Patent No. 5,852,171, which is a Divisional of U. S. Serial No. 08/289,699, filed on August 12, 1994, now U. S. Patent No. 5,695,993, by Kenji Fukudome and Charles T. Esmon entitled "*Cloning and Regulation of an Endothelial Cell Protein C/Activated Protein C Receptor.*"--

### In the Claims

Please amend the claims as follows.

Please cancel claims 1-15 and 19-21.

### Remarks

#### Prior Restriction Requirements

The claims of the original application, U.S. Serial No. 08/289,699 filed August 12, 1994, by Kenji Fukudome and Charles T. Esmon entitled "Cloning and Regulation of an Endothelial Cell Protein C/activated Protein C Receptor", which issued as U.S. Patent No. 5,695,993, with claims drawn to nucleic acid molecules that encode the endothelial cell protein C/activated protein C receptor and expression vectors that express these molecules.

The claims in U.S. Serial No. 08/878, 283, filed on June 18, 1997, now U.S. Patent No. 5,852,171, was a divisional of U.S. Serial No. 08/289,699, filed August 12, 1994 by Kenji Fukudome and Charles T. Esmon entitled "Cloning and Regulation of an Endothelial Cell Protein C/activated Protein C Receptor", and issued as U.S. Patent No. 5,695,993, with claims drawn to isolated endothelial cell protein C/activated protein C receptor proteins.

This is a divisional of these applications.

The original parent application was restricted requirement into eight groups: Group I, claims 1-6, drawn to a receptor protein; Group II, claims 7-13, drawn to a nucleic acid encoding a receptor; Group III, claims 14 and 15, drawn to a nucleic acid probes; group IV, claims 16 and 17, drawn to a method for enhancing an inflammatory response; Group V, claim 18, drawn to a


U.S.S.N. Divisional of 09/182,616  
Filed: August 18, 1999  
PRELIMINARY AMENDMENT

method of inhibiting an inflammatory response; Group VI, claims 19-21, drawn to an antibody to a receptor; Group VII, drawn to an *in vitro* screening method; and Group VIII, drawn to methods for screening patients. Groups II and III were then combined into the same group and prosecuted, ultimately issuing in United States Patent No. 5,695,993. Divisional application U.S. Serial Number 08/878,283 was filed June 18, 1997 and issued as U.S. Patent No. 5,852,171 with the claims of Group I, claims 1-6.

Group VI, claims 15-21, are currently being prosecuted in U.S. Serial No. 09/182,616, filed on October 29, 1998. The claims of Groups IV, V, VII, and VIII are currently pending in the present application upon entry of this Preliminary Amendment. It is believed these claims should be examined together.

A copy of the claims as pending upon entry of this Preliminary Amendment is attached in an appendix for the convenience of the Examiner.

Respectfully submitted,



\_\_\_\_\_  
Patrea L. Pabst  
Reg. No. 31,284

Date: August 20, 1999

ARNALL GOLDEN & GREGORY, LLP  
2800 One Atlantic Place  
1201 West Peachtree Street  
Atlanta, GA 30309-3450  
(404) 873-8794  
(404) 873-8795 (fax)

## APPENDIX: PENDING CLAIMS

16. A method for enhancing an inflammatory response involving blocking of protein C or activated protein C binding to an endothelial cell protein C/activated protein C receptor comprising administering to a patient in need of treatment thereof an amount of a compound blocking binding of protein C or activated protein C to the receptor. tumors

17. The method of claim 16 wherein the compound is selected from the group consisting of antibodies and fragments of antibodies to the receptor, nucleic acid sequences inhibiting expression of the receptor, and synthetic or natural compounds other than proteins, peptides or nucleic acid sequences which inhibit binding.

18. A method for inhibiting an inflammatory response involving administration of a compound selected from the group consisting of EPCR or EPCR fragments and substances that upregulate EPCR expression to a patient in need of treatment thereof.

22. A method for screening for a compound which alters the binding of an endothelial receptor protein to protein C or activated protein C comprising providing an assay for binding of protein C or activated protein C to the receptor protein,

    adding the compound to be tested to the assay, and

    determining if the amount of protein C or activated protein C which is bound to the receptor protein is altered as compared to binding in the absence of the compound to be tested.

23. A method for screening patients for abnormal receptor protein activity or function comprising

    determining the presence of an endothelial cell surface receptor binding protein C and activated protein C, and

    comparing the receptor to determine if the quantity present or the function of the receptor is equivalent to that present in normal cells.

APPLICATION

FOR

UNITED STATES LETTERS PATENT

BY

KENJI FUKUDOME

AND

CHARLES T. ESMON

FOR

CLONING AND REGULATION OF AN ENDOTHELIAL CELL  
PROTEIN C/ACTIVATED PROTEIN C RECEPTOR

CLONING AND REGULATION OF AN ENDOTHELIAL CELL  
PROTEIN C/ACTIVATED PROTEIN C RECEPTOR

Background of the Invention

The present invention is generally in the area of cloning, expression, and regulation of an endothelial cell protein C/activated protein C receptor.

Protein C plays a major role in the regulation of blood coagulation. Patients deficient in protein C usually exhibit life threatening thrombotic-complications in infancy (Seligsohn et al., 5 (1984) N. Engl. J. Med. 310, 559-562; Esmon, (1992) Trends Cardiovasc. Med. 2, 214-220) that are corrected by protein C administration (Dreyfus et al., (1991) N. Engl. J. Med. 325, 1565-1568). In addition, activated protein C (APC) can prevent the lethal effects of *E. coli* in baboon models of gram negative sepsis (Taylor 10 et al., (1987) J. Clin. Invest. 79; U.S. Patent No. 15 5,009,889 to Taylor and Esmon) and preliminary clinical results suggest that protein C is effective 20 in treating certain forms of human septic shock (Gerson et al., (1993) Pediatrics 91, 418-422). These results suggest that protein C may both control coagulation and influence inflammation. Indeed, inhibition of protein S, an important component of the protein C pathway, exacerbates the response of 25 primates to sublethal levels of *E. coli* and augments the appearance of TNF in the circulation (Taylor et al., (1991) Blood 78, 357-363). The mechanisms involved in controlling the inflammatory response remain unknown.

30 Protein C is activated when thrombin, the terminal enzyme of the coagulation system, binds to an endothelial cell surface protein, thrombomodulin

(Esmon, (1989) J. Biol. Chem. 264, 4743-4746; Dittman and Majerus, (1990) Blood 75, 329-336; Dittman, (1991) Trends Cardiovasc. Med. 1, 331-336). In cell culture, thrombomodulin transcription is blocked by exposure of endothelial cells to tumor necrosis factor (TNF) (Conway and Rosenberg, (1988) Mol. Cell. Biol. 8, 5588-5592) and thrombomodulin activity and antigen are subsequently internalized and degraded (Lentz et al., (1991) Blood 77, 543-550, Moore, K.L., et.al., (1989) Blood 73, 159-165). In addition, C4bBP, a regulatory protein of the complement system, binds protein S to form a complex that is functionally inactive in supporting APC anticoagulant activity *in vitro* (Dahlbäck, (1986) J. Biol. Chem. 261, 12022-12027) and *in vivo* (Taylor, et al., 1991). Furthermore, C4bBP behaves as an acute phase reactant (Dahlbäck, (1991) Thromb. Haemostas. 66, 49-61). Thus, proteins of this pathway not only appear to regulate inflammation, but they also interact with components that regulate inflammation, and they themselves are subject to down regulation by inflammatory mediators.

Given the central role of the protein C pathway in regulating the host response to inflammation and the critical role of the pathway in controlling blood coagulation, it is important to identify and characterize all of the components that interact with the system. This is especially true since the molecular basis of the anti-inflammatory effects of the protein C pathway components have yet to be elucidated at the molecular level.

It is therefore an object of the present invention to provide a cellular receptor for protein C and activated protein C.

It is a further object of the present invention to provide nucleotide sequences encoding the

cellular receptor and amino acid characterization of the receptor which allows expression of recombinant native and modified forms of the receptor.

invention to provide methods of modulating the inflammatory response involving protein C and activated protein C.

## Summary of the Invention

An endothelial cell protein C binding protein (referred to herein as "EPCR") has been cloned and characterized. The protein is predicted to consist of 238 amino acids, which includes a 15 amino acid signal sequence at the N-terminus, and a 23 amino acid transmembrane region which characterizes the receptor as a type 1 transmembrane protein. The protein binds with high affinity to both protein C and activated protein C ( $K_d=30$  nM) and is calcium dependent. The message and binding function of the receptor are both down regulated by cytokines such as TNF.

These results identify a new member of a complex pathway that, like other members of the pathway, is subject to regulation by inflammatory cytokines, and can therefore be used to modulate inflammatory reactions in which protein C or activated protein C is involved. Inhibition of the inflammatory response can be obtained by infusing soluble EPCR. Alternatively, localizing EPCR to surfaces in contact with blood will render the surfaces anticoagulant by virtue of the ability of EPCR to bind and concentrate the anticoagulant activated protein C at the surface. Alternatively, the function of EPCR can be enhanced by overexpressing

the EPCR in endothelium that could be used to coat vascular grafts in patients with vascular disease or on stents in cardiac patients.

#### Brief Description of the Drawings

Figures 1A, 1B and 1C are flow cytometric analyses of F1-APC (fluorescent labelled activated protein C) binding to HUVEC (human umbilical vein endothelial cells). Figure 1A is a graph of cell number versus log of fluorescence intensity, demonstrating F1-APC binding to HUVEC. HUVEC ( $1 \times 10^5$ ) were incubated at room temperature without (dotted line) or with 160 nM of F1-APC (solid line) in the presence of 1.3 mM CaCl<sub>2</sub>. After washing, bound APC was analyzed by flow cytometry. Figure 1B is a graph of fluorescence intensity versus F1-APC concentration (nM) demonstrating the concentration dependence of F1-APC binding to HUVEC. HUVEC were incubated with F1-APC in the absence (open circles) or presence of 1.3 mM CaCl<sub>2</sub> (closed circles) and binding was measured as in A. Mean channel fluorescence intensity is plotted for each F1-APC concentration (between 0 and 800 nM). Figure 1C is a graph of the percent of mean fluorescence versus unlabeled protein concentration ( $\mu\text{g}/\text{ml}$ ), demonstrating the effects of unlabeled proteins on F1-APC binding to HUVEC. F1-APC binding to HUVEC was carried out in the presence of the indicated concentrations (between 0 and 100  $\mu\text{g}/\text{ml}$ ) of unlabeled APC, protein C, protein S, factor X and Xa or recombinant Gla-domainless protein C (rGDPC).

Figures 2A, 2B, 2C and 2D are graphs of <sup>125</sup>I-APC Binding to HUVEC Monolayers. Figure 2A is a graph of the bound APC ( $\text{cpm} \times 10^3$ ) versus time (min),

showing the time course of  $^{125}\text{I}$ -APC binding to HUVEC. HUVEC monolayers ( $1.2 \times 10^5$  cells) were incubated at 4°C with 32 nM (filled squares) or 8 nM (open squares)  $^{125}\text{I}$ -APC. At the indicated times, cells were washed and bound radioactivity was measured. Figure 2B is a graph of bound APC ( $\text{cpm} \times 10^3$ ) versus unlabeled protein (nM) demonstrating the effects of unlabeled APC and rGDPC on  $^{125}\text{I}$ -APC binding to HUVEC. HUVEC were incubated at 4°C for one hour with  $^{125}\text{I}$ -labeled APC in the presence of the indicated concentrations (between 01 and approximately 1000 nM) of unlabeled-APC (open circles) or rGDPC (closed circles). After washing, bound radioactivity was measured. Figure 2C is a graph of bound APC (fmol/well) versus free APC (nM) demonstrating the concentration dependence of  $^{125}\text{I}$ -APC binding to HUVEC. Monolayers of HUVEC were incubated with the concentrations of  $^{125}\text{I}$ -APC indicated as described above. Specific binding was determined as described below. Figure 2D is a Scatchard analysis of  $^{125}\text{I}$ -APC binding to HUVEC. Each value was calculated from the data shown in Figure 2C.

Figures 3A and 3B are flow cytometric analyses of F1-APC binding to 293T cells transfected with a cDNA clone of EPCR. Cells were transfected with a clone EPCR/pEF-BOS or pEF-BOS (negative control) by the calcium/phosphate method. After 24 h, cells were harvested and F1-APC binding was performed in the absence (dotted lines) or presence of 1.3 mM CaCl<sub>2</sub> (solid lines).

Figure 4 is the predicted protein structure of EPCR based on nucleotide sequence, predicted amino acid sequence and a hydropathy plot of EPCR. The signal sequence and transmembrane region are indicated with the solid bars.

Figure 5 is a comparison of the amino acid sequence of EPCR to the amino acid sequences of other members of the CD1 family and CCD41. The EPCR sequence is shown in the first line and compared to murine CCD41 (second line), human CD1d (third line) and murine CD1.2 (fourth line). Identities with EPCR are indicated by open boxes. Residues that are conserved between EPCR and all of the human CD1 family members are indicated by a double asterisk. Residues shared with one or more members of the CD1 family are indicated by a single asterisk.

Figure 6 is a comparison of the amino acid sequence of human EPCR (first line) to the amino acid sequence of murine EPCR (second line). Identities are indicated by boxes. Similarities are indicated with an asterisk.

#### Detailed Description of the Invention

##### I. Cloning and Characterization of EPCR.

Human protein C and activated protein C are shown to bind to endothelium specifically, selectively and saturably ( $K_d = 30$  nM, 7000 sites per cell) in a  $\text{Ca}^{2+}$  dependent fashion. FL-APC binding to various human cell lines were examined, and found that the binding was HUVEC specific. A human kidney cell line transformed with SV40 large T antigen, 293T cells, expressed very few of these binding sites. A HUVEC cDNA library was constructed using the powerful mammalian expression vector, pEF-BOS (Mizushima and Nagata, (1990) Nucleic Acids Res. 18, 5322). Plasmid DNA was prepared from subpools of independent colonies (2,500 colonies per pool), and transfected into 293T cells, using the method of Kaisho et al., (1994)

Proc. Natl. Acad. Sci. (USA) 91, 5325. FL-APC binding was analyzed on a flow cytometer. One of eight subpools gave a positive signal. This subpool was divided into 20 subpools and rescreened. After three rounds of enrichment, one positive clone, EPCR-1, was isolated. EPCR-1 carries a 1.3 kb insert. When transfected into 293T cells, this clone was capable of expressing the calcium-dependent binding site for FL-APC on the 293T cell surface.

Expression cloning revealed a 1.3 kb cDNA that coded for a type I transmembrane glycoprotein capable of binding protein C. This protein appears to be a member of the CD1/MHC superfamily. Like thrombomodulin, the receptor involved in protein C activation, the endothelial cell protein C receptor (EPCR) function and message are both down regulated by exposure of endothelium to TNF. Identification of EPCR as a member of the CD1/MHC superfamily provides insights into the role of this receptor for protein C in regulating the inflammatory response.

#### Materials and Methods

##### Protein Preparation

Human protein C (Esmon et al., 1993) Meths. Enzymol. 222, 359-385), APC (Esmon et al., 1993), recombinant gla domainless protein C (rGDPC) (Rezaie et al., 1992) J. Biol. Chem. 267, 11701-11704), protein S (Taylor et al., 1991), factor X and factor Xa (Le Bonniec et al., 1992) J. Biol. Chem. 267, 6970-6976) were prepared as described in the cited publications.

Selective labeling of the active site of APC with fluorescein was performed by the method of Bock (Bock, P.E. (1988) Biochemistry 27, 6633-6639). In brief, N<sup>a</sup>[(acetylthio)acetyl]-D-Phe-Pro-Arg-CH<sub>2</sub>C1 (200

μM) was reacted with 40 μM APC for 1 hour at room temperature. After dialysis, the covalently modified APC was incubated at room temperature for one hour with 200 μM 5-(iodoacetamido)fluorescein (Molecular Probes). Free fluorescein was removed by gel filtration on a PD-10 column (Pharmacia). With this method, each molecule of fluoresceinated APC (FI-APC) contains a single dye at the active site and hence all of the fluorescent molecules behave identically.

Iodogen (Pierce) was used to radiolabel APC with Na[<sup>125</sup>I] (Amersham) according to the manufacturer's protocol in the presence of 5 mM CaCl<sub>2</sub>. Free <sup>125</sup>I was removed by gel filtration on a PD-10 column. The specific activity of the <sup>125</sup>I-APC was 1 x 10<sup>4</sup> cpm/ng protein.

#### Cell Culture

Human umbilical vein endothelial cells (HUVEC) were isolated from fresh umbilical-cords by collagenase treatment and cultured in medium 199 containing 15% fetal bovine serum, 10 μg/ml heparin, and 0.5% endothelial cell growth supplement prepared from bovine brain extract (Maciag et al., (1979) Proc. Natl. Acad. Sci. (USA) 76, 5674-5678). HOS (ATCC CRL 1543), HEp-2 (ATCC CCL 23) and 293 cells (ATCC CRL 1573) transformed with SV40 large T antigen (293T, a gift from Dr. Kenji Oritani) were maintained in Earl's MEM supplemented with 10% fetal bovine serum. The human lymphocyte cell lines, Jurkat, MOLT3 (ATCC CRL 1552), Jijoye (ATCC CCL 87), Raji (ATCC CCL 86), U-937 (ATCC CRL 1593), HL-60 (ATCC CCL 240), and HEL (ATCC TIB 180), were maintained in RPMI-1640 medium supplemented with 10% fetal bovine serum.

#### Flow Cytometric Analysis of FI-APC Binding to Cells

Adherent cells were harvested by incubation

at 37°C for 5 min in phosphate buffered saline (PBS) containing 0.02% EDTA. Cells were washed twice with EDTA/PBS and then once with Hank's balanced salt solution (HBSS). They were resuspended in HBSS containing 1% bovine serum albumin (BSA) and 0.02% sodium azide (binding buffer). Cells ( $1 \times 10^5$ ) were incubated at room temperature for 45 min with F1-APC in the dark. After washing, they were resuspended in the binding buffer containing 0.5  $\mu$ g/ml of propidium iodide. Bound F1-APC was analyzed on a flow cytometer, FACScan (Becton Dickinson). Living cells were gated on a dot plot display of forward-scatter (FSC) versus fluorescence-2 (FL2), and F1-APC binding was detected on the fluorescence-1 (FL-1) channel. All experiments were performed in duplicate.

#### <sup>125</sup>I-APC binding to HUVEC

Monolayers of HUVEC in 24-well microplates (Costar) ( $1 \times 10^5$  cells per well) were washed twice with EDTA/PBS and once with ice-cold HBSS. Cells were then incubated at 4°C for one hour in the binding buffer with <sup>125</sup>I-APC. After washing three times with ice-cold HBSS, cells were released with the EDTA buffer, and the bound radioactivity was measured in a gamma counter (Isodata 500). To determine non-specific, calcium-independent adsorption of radioactivity, the cells were washed with EDTA/PBS and residual radioactivity in the cell pellet was measured. Non-specific binding of radioactivity was consistently less than 5% of the specific binding. The data was analyzed using the Enzfitter program (Elsevier Biosoft, Cambridge, U.K.).

**Construction of HUVEC cDNA Library**

Poly-A RNA was isolated from HUVEC ( $1 \times 10^8$  cells) using the FastTrack™ mRNA isolation kit (Invitrogen). cDNA was synthesized from 3  $\mu$ g of poly-A RNA using a Librarian™ I kit (Invitrogen). A *Bst*X I adaptor was ligated, double stranded cDNA was fractionated by agarose gel electrophoresis, and cDNA longer than 700 bp was ligated into a mammalian expression vector, pEF-BOS (Mizushima and Nagata, 1990; this vector was a kind gift from Dr. S. Nagata). The construct was transfected into *E. coli*-DH10B by electroporation (Bio-Rad Gene Pulser™). The library consisted of  $8 \times 10^6$  independent colonies with an average size of 2.0 kb.

**Expression Cloning and Sequence Analysis**

Approximately  $2 \times 10^4$  independent colonies were divided into eight subpools (each containing 2,500 independent colonies) and plasmid DNA was prepared from each subpool. Sub-confluent 293T cells in 24-well microplates were transfected with 1  $\mu$ g of the DNA by the calcium/phosphate method (Graham and Van Der Eb, (1973) *Virology* 52, 456-467). After 20 hours, the medium was changed, and culture was continued for another 24 hours. The subpools were screened for F1-APC binding by FACS analysis as described above. The positive library pool was then divided into 20 new pools and rescreened. After three rounds of screening, 96 individual clones were tested and one positive clone was identified.

The insert (1.3 kb) was subcloned into pBluescript™ (Stratagene), and the nucleotide sequence was determined using a Sequenase™ version 2.0 DNA Sequencing kit (USB). Nucleotide and protein database search employed the BLAST™ (NCBI) and

FASTA™ programs (GCG) with GenBank, EMBL, and SwissProt databases.

#### Northern Blot Analysis

Total RNAs (15 µg) from various cells were isolated, electrophoresed through formaldehyde agarose gels and transferred to a nylon membrane (Hybond-N™, Amersham). The 483 bp *Xba* I fragment from the 5' end of the EPCR cDNA was labeled by random priming according to the manufacturer's instructions (Multiprime™ DNA labeling system, Amersham) and used for hybridization.

#### Protein C and APC Binding to HUVEC

Endothelial cells in suspension bound FL-APC, as monitored by flow cytometry, and demonstrated in Figure 1A. Binding was saturable and  $\text{Ca}^{2+}$  dependent, as shown by Figure 1B. Optimal binding required at least 1 mM  $\text{Ca}^{2+}$ . FL-APC was displaced from the cell surface by APC and protein C equivalently, as shown by Figure 1C. The homologous Gla-domain containing proteins, protein S, factor X, and its active form, factor Xa, failed to displace bound F1-APC, suggesting that there is a specific binding site for APC on the endothelial cell surface. Protein C binding was dependent on the Gla domain, since recombinant gla-domainless protein C (rGDPC) failed to displace F1-APC.

Detailed binding studies were also performed with  $^{125}\text{I}$ -labeled APC and monolayers of HUVEC, as shown by Figures 2A, 2B, 2C and 2D. The binding analysis indicated 7,000 sites per cell and a  $K_d=30$  nM. This affinity is similar to that estimated from Figure 1.

Endothelial cell surface thrombomodulin can interact with protein C and APC. The  $K_d$  (greater than 1 µM) (Hogg et al., (1992) *J. Biol. Chem.* 267,

703-706; Olsen et al., (1992) Biochemistry 31,  
746-754), however, is much higher than that of the  
binding site described above with respect to the new  
receptor. Furthermore, polyclonal and monoclonal  
antibodies against thrombomodulin that inhibit protein  
C activation did not inhibit the binding. Protein S  
also can interact with protein C and APC (Dahlbäck et  
al., (1992) Biochemistry 31, 12769-12777), but F1-APC  
binding to HUVEC was not influenced by protein S  
addition. Furthermore, polyclonal and monoclonal  
antibodies to protein S did not inhibit the binding.  
These results indicate the binding site for protein C  
and APC on endothelium is distinct from these known  
molecules.

Nucleotide and Predicted Protein Structure  
Analysis of EPCR

The insert was subcloned into pBluescript,  
and the nucleotide sequence was determined, as shown  
in Sequence ID No. 1. The cDNA shown in Sequence ID  
No. 1 consists of 1302 bp, including a translation  
initiation ATG codon (AGGATGT, (Kozak, (1986) Cell 44,  
283-292) at the 5'-end at nucleotides 25-27 of  
Sequence ID No. 1. A potential polyadenylation signal  
sequence, AATAAA, (Proudfoot and Brownlee, (1976)  
Nature 263, 211-214) begins at nucleotide 1267 of  
Sequence ID No. 1, just 18 bp upstream of the poly(A)  
sequence.

The cDNA is predicted to code for a protein  
of 238 amino acids (Sequence ID No. 2), which includes  
a 15 amino acid signal sequence (von Heijne, (1986)  
Nucleic Acids Res. 14, 4683-4690) at the N-terminal.  
Therefore, the mature protein is predicted to contain  
223 amino acids. Sequence ID No. 2 is the predicted  
amino acid sequence of EPCR. Amino acids 1-15 of  
Sequence ID No. 2 (MLTTLLPILLLSGWA) are the putative

signal sequence determined by the method of von Heijne (von Heijne, 1986). Amino acids 211-236 of Sequence ID No. 2 (LVLGVLVGGFIIAGVAVGIFLCTGGR) are the putative transmembrane domain. Potential N-glycosylation sites are present at amino acids 47-49, 64-66, 136-138, and 172-174 of Sequence ID No. 2. Extracellular cysteine residues are present at amino acids 17, 114, 118, and 186 of Sequence ID No. 2. A potential transmembrane region (Engelman et al., (1986) Annu. Rev. Biophys. Biophys. Chem. 15, 321-53 ) consisting of 23 amino acids was identified at the C-terminal end (beginning at amino acid 216 of Sequence ID No. 2).

The protein is predicted to be a type 1 transmembrane protein. The extracellular domain contains four potential N-glycosylation sites and four Cys residues. The cytoplasmic region contains only three amino acids and terminates with a Cys, which could be acylated to something or involved in heterodimer formation with another peptide.

Although described with reference to cloning and expression of the protein encoding sequence, larger amounts of protein can be obtained by expression in suitable recombinant host systems, such as mammalian, yeast, bacteria, or insect cells. Isolation can be facilitated by making antibodies to the recombinant protein which are then immobilized on substrates for use in purification of additional receptors, as described below.

As used herein, the nucleotide sequences encoding the receptor include the sequence shown in Sequence ID No. 1, and sequences having conservative substitutions, additions or deletions thereof which hybridize to Sequence ID No. 1 under stringent conditions. As used herein, the amino acids sequences constituting the receptor include the sequence shown

in Sequence ID No. 2, and sequences having conservative substitutions, additions or deletions thereof which form a receptor having functionally equivalent biological activity. It is well known to those skilled in the art what constitutes conservative substitutions, additions or deletions, and which could be readily ascertained as encoding, or forming, a functionally equivalent receptor molecule using the functional assays described herein.

The hydropathic plot shown in Figure 4 was performed according to the method of Goldman et al (Engelman et al., 1994) (solid line) and that of Kyte and Doolittle (1982) J. Mol. Biol. 157, 105-132 (dotted line).

DNA and protein database searches revealed that the sequence is related to the centrosome-associated, cell cycle dependent murine protein, CCD41, also referred as centrocyclin (Rothbarth et al., (1993) J. Cell Sci. 104, 19-30), as shown by Figure 5. The similarity in the published sequence of murine CCD41 with human EPCR led to the cloning and sequencing of the murine EPCR. The sequence of murine EPCR is shown in Figure 6. It is distinct from the published sequence of CCD41.

The EPCR amino acid sequence was also related to, but quite distinct from, the CD1/MHC superfamily and the murine CD1.2, as also shown by Figure 5. Based on the homology to CD1/MHC, it is likely that EPCR contains two domains consisting of residues 17-114 and 118-188. Of the CD1 family members, CD1d is the most similar to EPCR. In the mouse, CCD41 is associated exclusively with the centrosome during G<sub>1</sub> but becomes detectable elsewhere during the cell cycle, reaching a maximum during G<sub>2</sub>,

except during the G<sub>2</sub>/M phase (Rothbarth et al., 1993). EPCR expression appears restricted to endothelium, which would not be expected for a cell cycle associated protein.

The identification of the protein C receptor on endothelium suggests that the endothelial cell binds protein C/APC through three distinct mechanisms. In addition to EPCR, protein S can bind APC/protein C on negatively charged membrane surfaces that include the endothelium (Stern et al., (1986) J. Biol. Chem. 261, 713-718), but this is not cell type specific (Dahlbäck et al., 1992). Thrombomodulin in complex with thrombin can bind protein C and APC (Hogg et al., 1992). On endothelium, the protein S binding sites (Nawroth and Stern, (1986) J. Exp. Med. 163, 740-745), thrombomodulin (Esmon, 1989) and EPCR are all down regulated by cytokines, indicating that inflammation can impair protein C pathway function at multiple levels.

The homology to the CD1/MHC family of proteins is especially interesting since it provides indications as to the function of EPCR. The CD1/MHC family has three extracellular domains termed  $\alpha$ 1,2 and 3. The extracellular domain of EPCR contains four Cys residues that appear to correspond to two distinct domains. EPCR lacks the third domain of the CD1/MHC family, but the two domains have significant homology to the  $\alpha$ 1 and  $\alpha$ 2 domains of the CD1 protein family and the  $\alpha$ 2 domain of the MHC class 1 protein, suggesting that these proteins evolved from a common ancestor. The first domain of EPCR, residues 17-114, contains two potential N glycosylation sites and is rich in  $\beta$  strand structure, suggesting that it may form a  $\beta$  sheet. Despite the  $\beta$  strand structure, consensus

5 sequences (Williams and Barclay, (1988) Ann. Rev. Immunol. 6, 381-405) for the immunoglobulin superfamily of receptors are absent. The second domain of EPCR, residues 118-188, contains two additional N glycosylation sites and, like the CD1/MHC family, this domain is predicted to have limited  $\beta$  structure.

10 II. Modulation of Inflammation using EPCR.

15 *In vitro* studies have suggested anti-inflammatory activities for APC. For instance, an unusual carbohydrate sequence on protein C can inhibit inflammatory cell adhesion to selectins (Grinnell et al., (1994) Glycobiology, 4, 221-226) Modest inhibitory effects of APC have been reported on TNF production (Grey et al., (1993) Transplant. Proc. 25, 2913-2914). EPCR could contribute to these anti-inflammatory mechanisms. Since the homologous protein family, CD1, can be linked to CD8 (Ledbetter et al., (1985) J. Immunol. 134, 4250-4254), it is also possible that the protein C receptor is linked to another protein and signal through this second protein. One of the CD1 family members, CD1d, has been reported to promote T cell responses, possibly involving binding to CD8 (Panja et al., (1993) J. Exp. Med. 178, 1115-1119). CD1b has recently been reported to serve as an antigen presenting molecule (Porcelli et al., (1992) Nature 360, 593-597). The ability to bind protein C/APC could then be linked either directly or indirectly to signalling via direct interaction with cells of the immune system. Since the MHC class of proteins is involved in presentation of proteins to cell receptors, the concept of presentation of protein C/APC to inflammatory cells as a means of elaborating anti-inflammatory activity may also be involved. This includes modulation of enzyme

specificity such as occurs with thrombin-thrombomodulin interaction (Esmon, 1989). In this case, the EPCR-APC complex might cleave biologically active peptides from unknown substrates.

#### 5 EPCR mRNA Levels and APC Binding

To determine the cellular specificity of EPCR expression, the intensity of FL-APC binding to HUVEC was compared to several human cell lines. F1-APC bound strongly only to HUVEC, and not to any of the T, B, or monocytic cell lines tested. Cells were incubated at room temperature without or with 160 nM F1-APC in the presence of 1.3 mM CaCl<sub>2</sub>. Binding was analyzed by flow cytometry. Slight binding was demonstrated with the osteosarcoma line, HOS and the epidermoid carcinoma cell line, HEp-2.

15 Total RNA was extracted from these cells and hybridized with the EPCR cDNA probe for Northern Blot Analysis. EPCR mRNA was detected by Northern blot analysis for HUVEC, Jurkat, HEp-2, Raji, HOS, and U937. Among the cell lines tested, EPCR mRNA was detected at high levels only in HUVEC. The calculated mRNA size of 1.3 kb was identical to the size of the isolated cDNA. After prolonged exposure, a weak signal was also detected with the osteosarcoma cell line HOS and monocyte cell line U937. Thus, both APC binding and EPCR mRNA expression are very specific for endothelium.

#### 20 Effects of TNF on APC Binding and EPCR mRNA Levels

25 Several other members of the protein C anticoagulant pathway are subject to regulation by inflammatory cytokines (Esmon, 1989). For instance, endothelial cell surface thrombomodulin expression and message are known to be reduced by exposure of the 30 cells to TNF (Conway and Rosenberg, 1988; Lentz et

al., 1991). To determine if a similar process occurs with EPCR, HUVEC were treated with TNF and APC binding and expression of EPCR mRNA were examined. APC binding to HUVEC decreased in a time dependent fashion. EPCR activity decreased more rapidly than thrombomodulin antigen. HUVEC were cultured for 0, 6, 10  
5 24 and 48 hr, in the presence of TNF- $\alpha$  (10 ng/ml). Cells were harvested and residual F1-APC binding or thrombomodulin (TM) expression was analyzed by flow cytometry. Cell surface TM was stained with an anti-TM murine monoclonal antibody and FITC-conjugated anti-mouse IgG. The negative control is without added fluorescent ligand.

15 HUVEC were treated with 10 ng/ml of TNF- $\alpha$  for 0, 0.5, 1, 2, 3, 6, 10 and 24 hr, and message was extracted and detected as described above. The results demonstrated that the concentration of EPCR mRNA was also reduced by TNF treatment. Message levels and APC binding activity decreased in parallel. Therefore, the TNF mediated down-regulation of APC 20 binding to endothelium probably occurs at the level of mRNA expression.

Enhancement of inflammatory responses by blocking binding of endogenous molecules to EPCR can be achieved by administration of compounds binding to the receptor to a subject in need of inhibition. The degree of binding is routinely determined using assays such as those described above. Compounds which are effective include antibodies to the protein, fragments of antibodies retaining the binding regions, and peptide fragments of APC which include the Gla region. Inhibition of the inflammatory response could be obtained by infusing soluble EPCR. Alternatively, localizing EPCR to surfaces in contact with blood 25 would render the surfaces anticoagulant by virtue of 30 35

5 the ability of EPCR to bind and concentrate the anticoagulant APC at the surface. Alternatively, the function of EPCR could be enhanced by overexpressing the EPCR in endothelium used to coat vascular grafts in patients with vascular disease or on stents in cardiac patients.

10 The DNA sequence can also be used for screening for other homologous or structurally similar receptor proteins using hybridization probes.

15 These methods and reagents and pharmaceuticals are more readily understood by reference to the following.

Screening of patient samples for expression of receptor proteins.

20 Patients with thrombosis or hyperinflammatory conditions could be screened for defects in the EPCR gene. Sequence ID No. 1, and consecutive portions thereof of at least about seven nucleotides, more preferably fourteen to seventeen nucleotides, most preferably about twenty nucleotides, are useful in this screening using hybridization assays of patient samples, including blood and tissues. Screening can also be accomplished using antibodies, typically labelled with a fluorescent, radiolabelled, or enzymatic label, or by isolation of target cells and screening for binding activity, as described in the examples above. Typically, one would screen for expression on either a qualitative or quantitative basis, and for expression of functional receptor. Labelling can be with  $^{32}P$ ,  $^{35}S$ , fluorescein, biotin, or other labels routinely used with methods known to those skilled in the art for labelling of proteins and/or nucleic acid sequences.

25

30

*Hybridization Probes*

35 Reaction conditions for hybridization of an

oligonucleotide probe or primer to a nucleic acid sequence vary from oligonucleotide to oligonucleotide, depending on factors such as oligonucleotide length, the number of G and C nucleotides, and the composition of the buffer utilized in the hybridization reaction.

Moderately stringent hybridization conditions are generally understood by those skilled in the art as conditions approximately 25°C below the melting temperature of a perfectly base-paired double-stranded DNA. Higher specificity is generally achieved by employing incubation conditions having higher temperatures, in other words, more stringent conditions. In general, the longer the sequence or higher the G and C content, the higher the temperature and/or salt concentration required. Chapter 11 of the well-known laboratory manual of Sambrook et al., MOLECULAR CLONING: A LABORATORY MANUAL, second edition, Cold Spring Harbor Laboratory Press, New York (1990) (which is incorporated by reference herein), describes hybridization conditions for oligonucleotide probes and primers in great detail, including a description of the factors involved and the level of stringency necessary to guarantee hybridization with specificity.

The preferred size of a hybridization probe is from 10 nucleotides to 100,000 nucleotides in length. Below 10 nucleotides, hybridized systems are not stable and will begin to denature above 20°C. Above 100,000 nucleotides, one finds that hybridization (renaturation) becomes a much slower and incomplete process, as described in greater detail in the text MOLECULAR GENETICS, Stent, G.S. and R. Calender, pp. 213-219 (1971). Ideally, the probe should be from 20 to 10,000 nucleotides. Smaller nucleotide sequences (20-100) lend themselves to production by automated organic synthetic techniques.

Sequences from 100-10,000 nucleotides can be obtained from appropriate restriction endonuclease treatments. The labeling of the smaller probes with the relatively bulky chemiluminescent moieties may in some cases interfere with the hybridization process.

*Generation of Antibodies for Diagnostic or Therapeutic Use*

Antibodies to the receptor proteins can also be generated which are useful in detection, characterization or isolation of receptor proteins, as well as for modifying receptor protein activity, in most cases, through inhibition of binding. Antibodies are generated by standard techniques, using human or animal receptor proteins. Since the proteins exhibit high evolutionary conservation, it may be advantageous to generate antibodies to a protein of a different species of origin than the species in which the antibodies are to be tested or utilized, looking for those antibodies which are immunoreactive with the most evolutionarily conserved regions. Antibodies are typically generated by immunization of an animal using an adjuvant such as Freund's adjuvant in combination with an immunogenic amount of the protein administered over a period of weeks in two to three week intervals, then isolated from the serum, or used to make hybridomas which express the antibodies in culture. Because the methods for immunizing animals yield antibody which is not of human origin, the antibodies could elicit an adverse effect if administered to humans. Methods for "humanizing" antibodies, or generating less immunogenic fragments of non-human antibodies, are well known. A humanized antibody is one in which only the antigen-recognized sites, or complementarily-determining hypervariable regions (CDRs) are of non-human origin, whereas all framework

regions (FR) of variable domains are products of human genes. These "humanized" antibodies present a lesser xenographic rejection stimulus when introduced to a human recipient.

To accomplish humanization of a selected mouse monoclonal antibody, the CDR grafting method described by Daugherty, et al., (1991) Nucl. Acids Res., 19:2471-2476, incorporated herein by reference, may be used. Briefly, the variable region DNA of a selected animal recombinant anti-idiotypic ScFv is sequenced by the method of Clackson, T., et al., (1991) Nature, 352:624-688, incorporated herein by reference. Using this sequence, animal CDRs are distinguished from animal framework regions (FR) based on locations of the CDRs in known sequences of animal variable genes. Kabat, H.A., et al., Sequences of Proteins of Immunological Interest, 4th Ed. (U.S. Dept. Health and Human Services, Bethesda, MD, 1987). Once the animal CDRs and FR are identified, the CDRs are grafted onto human heavy chain variable region framework by the use of synthetic oligonucleotides and polymerase chain reaction (PCR) recombination. Codons for the animal heavy chain CDRs, as well as the available human heavy chain variable region framework, are built in four (each 100 bases long) oligonucleotides. Using PCR, a grafted DNA sequence of 400 bases is formed that encodes for the recombinant animal CDR/human heavy chain FR protection.

The immunogenic stimulus presented by the monoclonal antibodies so produced may be further decreased by the use of Pharmacia's (Pharmacia LKB Biotechnology, Sweden) "Recombinant Phage Antibody System" (RPAS), which generates a single-chain Fv fragment (ScFv) which incorporates the complete

5 antigen-binding domain of the antibody. In the RPAS, antibody variable heavy and light chain genes are separately amplified from the hybridoma mRNA and cloned into an expression vector. The heavy and light chain domains are co-expressed on the same polypeptide chain after joining with a short linker DNA which codes for a flexible peptide. This assembly generates a single-chain Fv fragment (ScFv) which incorporates the complete antigen-binding domain of the antibody.

10 Compared to the intact monoclonal antibody, the recombinant ScFv includes a considerably lower number of epitopes, and thereby presents a much weaker immunogenic stimulus when injected into humans.

15 The antibodies can be formulated in standard pharmaceutical carriers for administration to patients in need thereof. These include saline, phosphate buffered saline, and other aqueous carriers, and liposomes, polymeric microspheres and other controlled release delivery devices, as are well known in the art. The antibodies can also be administered with adjuvant, such as muramyl dipeptide or other materials approved for use in humans (Freund's adjuvant can be used for administration of antibody to animals).

20  
25  
Screening for drugs modifying or altering  
the extent of receptor function or  
expression

30 The receptor proteins are useful as targets for compounds which turn on, or off, or otherwise regulate binding to these receptors. The assays described above clearly provide routine methodology by which a compound can be tested for an inhibitory effect on binding of PC or APC. The *in vitro* studies of compounds which appear to inhibit binding selectively to the receptors are then confirmed by animal testing. Since the molecules are so highly

evolutionarily conserved, it is possible to conduct studies in laboratory animals such as mice to predict the effects in humans.

In cases where inflammatory mediators or vascular disease down regulate EPCR, it would be advantageous to increase its concentration *in vivo* on endothelium. The binding assays described here and the gene sequence allow assays for increased EPCR expression. Similar approaches have been taken with thrombomodulin and investigators have shown that cyclic AMP (Maruyama,I. et al. (1991) Thrombosis Research **61**, 301-310) and interleukin 4 (Kapiotis,S. et al., (1991) Blood **78**, 410-415) can elevate thrombomodulin expression. The ability to screen such drugs or drugs that block TNF down regulation of EPCR provide an approach to elevating EPCR expression *in vivo* and thus enhancing anticoagulant and anti-inflammatory activity.

Studies based on inhibition of binding are predictive for indirect effects of alteration of receptor binding. For example, inhibition of binding of APC or increased expression of TNF is predictive of inhibition of EPCR function.

Assays for testing compounds for useful activity can be based solely on interaction with the receptor protein, preferably expressed on the surface of transfected cells such as those described above. Proteins in solution or immobilized on inert substrates can also be utilized. These can be used to detect inhibition or enhancement in binding of PC or APC

Alternatively, the assays can be based on interaction with the gene sequence encoding the receptor protein, preferably the regulatory sequences directing expression of the receptor protein. For

example, antisense which binds to the regulatory sequences, and/or to the protein encoding sequences can be synthesized using standard oligonucleotide synthetic chemistry. The antisense can be stabilized for pharmaceutical use using standard methodology (encapsulation in a liposome or microsphere; introduction of modified nucleotides that are resistant to degradation or groups which increase resistance to endonucleases, such as phosphorothiodates and methylation), then screened initially for alteration of receptor activity in transfected or naturally occurring cells which express the receptor, then *in vivo* in laboratory animals. Typically, the antisense would inhibit expression. However, sequences which block those sequences which "turn off" synthesis can also be targeted.

The receptor protein for study can be isolated from either naturally occurring cells or cells which have been genetically engineered to express the receptor, as described in the examples above. In the preferred embodiment, the cells would have been engineered using the intact gene.

*Random generation of receptor or receptor encoding sequence binding molecules.*

Molecules with a given function, catalytic or ligand-binding, can be selected for from a complex mixture of random molecules in what has been referred to as "in vitro genetics" (Szostak, (1992) TIBS 19:89). One synthesizes a large pool of molecules bearing random and defined sequences and subjects that complex mixture, for example, approximately  $10^{15}$  individual sequences in 100  $\mu\text{g}$  of a 100 nucleotide RNA, to some selection and enrichment process. For example, by repeated cycles of affinity chromatography

and PCR amplification of the molecules bound to the ligand on the column, Ellington and Szostak (1990) estimated that 1 in  $10^{10}$  RNA molecules folded in such a way as to bind a given ligand. DNA molecules with such ligand-binding behavior have been isolated (Ellington and Szostak, 1992; Bock et al, 1992).

*Computer assisted drug design*

Computer modeling technology allows visualization of the three-dimensional atomic structure of a selected molecule and the rational design of new compounds that will interact with the molecule. The three-dimensional construct typically depends on data from x-ray crystallographic analyses or NMR imaging of the selected molecule. The molecular dynamics require force field data. The computer graphics systems enable prediction of how a new compound will link to the target molecule and allow experimental manipulation of the structures of the compound and target molecule to perfect binding specificity. Prediction of what the molecule-compound interaction will be when small changes are made in one or both requires molecular mechanics software and computationally intensive computers, usually coupled with user-friendly, menu-driven interfaces between the molecular design program and the user.

Examples of molecular modelling systems are the CHARMM and QUANTA programs, Polymen Corporation, Waltham, MA. CHARMM performs the energy minimization and molecular dynamics functions. QUANTA performs the construction, graphic modelling and analysis of molecular structure. QUANTA allows interactive construction, modification, visualization, and analysis of the behavior of molecules with each other.

A number of articles review computer

modeling of drugs interactive with specific proteins, such as Rotivinen, et al., (1988) Acta Pharmaceutica Fennica 97, 159-166; Ripka, New Scientist 54-57 (June 16, 1988); McKinlay and Rossmann, (1989) Annu. Rev. Pharmacol. Toxicol. 29, 111-122; Perry and Davies, QSAR: Quantitative Structure-Activity Relationships in Drug Design pp. 189-193 (Alan R. Liss, Inc. 1989); Lewis and Dean, (1989) Proc. R. Soc. Lond. 236, 125-140 and 141-162; and, with respect to a model receptor for nucleic acid components, Askew, et al., (1989) J. Am. Chem. Soc. 111, 1082-1090. Other computer programs that screen and graphically depict chemicals are available from companies such as BioDesign, Inc., Pasadena, CA., Allelix, Inc, Mississauga, Ontario, Canada, and Hypercube, Inc., Cambridge, Ontario. Although these are primarily designed for application to drugs specific to particular proteins, they can be adapted to design of drugs specific to regions of DNA or RNA, once that region is identified.

Although described above with reference to design and generation of compounds which could alter binding, one could also screen libraries of known compounds, including natural products or synthetic chemicals, and biologically active materials, including proteins, for compounds which are inhibitors or activators.

*Generation of nucleic acid regulators*

Nucleic acid molecules containing the 5' regulatory sequences of the receptor genes can be used to regulate or inhibit gene expression *in vivo*. Vectors, including both plasmid and eukaryotic viral vectors, may be used to express a particular recombinant 5' flanking region-gene construct in cells depending on the preference and judgment of the skilled practitioner (see, e.g., Sambrook et al.,

Chapter 16). Furthermore, a number of viral and nonviral vectors are being developed that enable the introduction of nucleic acid sequences *in vivo* (see, e.g., Mulligan, (1993) Science, 260, 926-932; United States Patent No. 4,980,286; United States Patent No. 4,868,116; incorporated herein by reference).

Recently, a delivery system was developed in which nucleic acid is encapsulated in cationic liposomes which can be injected intravenously into a mammal. This system has been used to introduce DNA into the cells of multiple tissues of adult mice, including endothelium and bone marrow (see, e.g., Zhu et al., (1993) Science 261, 209-211; incorporated herein by reference).

The 5' flanking sequences of the receptor gene can also be used to inhibit the expression of the receptor. For example, an antisense RNA of all or a portion of the 5' flanking region of the receptor gene can be used to inhibit expression of the receptor *in vivo*. Expression vectors (e.g., retroviral expression vectors) are already available in the art which can be used to generate an antisense RNA of a selected DNA sequence which is expressed in a cell (see, e.g., U.S. Patent No. 4,868,116; U.S. Patent No. 4,980,286).

Accordingly, DNA containing all or a portion of the sequence of the 5' flanking region of the receptor gene can be inserted into an appropriate expression vector so that upon passage into the cell, the transcription of the inserted DNA yields an antisense RNA that is complementary to the mRNA transcript of the receptor protein gene normally found in the cell. This antisense RNA transcript of the inserted DNA can then base-pair with the normal mRNA transcript found in the cell and thereby prevent the mRNA from being translated. It is of course necessary to select

sequences of the 5' flanking region that are downstream from the transcriptional start sites for the receptor protein gene to ensure that the antisense RNA contains complementary sequences present on the mRNA.

5

Antisense RNA can be generated *in vitro* also, and then inserted into cells. Oligonucleotides can be synthesized on an automated synthesizer (e.g., Model 8700 automated synthesizer of Milligen-Bioscience, Burlington, MA or ABI Model 380B). In addition, antisense deoxyoligonucleotides have been shown to be effective in inhibiting gene transcription and viral replication (see e.g., Zamecnik et al., 10 1978) Proc. Natl. Acad. Sci. USA 75, 280-284; Zamecnik et al., (1986) Proc. Natl. Acad. Sci., 15 83, 4143-4146; Wickstrom et al., (1988) Proc. Natl. Acad. Sci. USA 85, 1028-1032; Crooke, (1993) FASEB J. 7, 533-539. Furthermore, recent work has shown that improved inhibition of expression of a gene by antisense oligonucleotides is possible if the antisense oligonucleotides contain modified nucleotides (see, e.g., Offensperger et. al., (1993) EMBO J. 12, 1257-1262 (*in vivo* inhibition of duck hepatitis B viral replication and gene expression by antisense phosphorothioate oligodeoxynucleotides); PCT WO 93/01286 Rosenberg et al., (synthesis of sulfurthioate oligonucleotides); Agrawal et al., 20 25 (1988) Proc. Natl. Acad. Sci. USA 85, 7079-7083 (synthesis of antisense oligonucleoside phosphoramidates and phosphorothioates to inhibit replication of human immunodeficiency virus-1); Sarin et al., (1989) Proc. Natl. Acad. Sci. USA 85, 7448-30 7794 (synthesis of antisense methylphosphonate oligonucleotides); Shaw et al., (1991) Nucleic Acids Res 19, 747-750 (synthesis of 3' exonuclease-resistant 35

oligonucleotides containing 3' terminal phosphoroamidate modifications); incorporated herein by reference).

The sequences of the 5' flanking region of receptor protein gene can also be used in triple helix (triplex) gene therapy. Oligonucleotides complementary to gene promoter sequences on one of the strands of the DNA have been shown to bind promoter and regulatory sequences to form local triple nucleic acid helices which block transcription of the gene (see, e.g., Maher et al., (1989) Science 245, 725-730; Orson et al., (1991) Nucl. Acids Res. 19, 3435-3441; Postal et al., (1991) Proc. Natl. Acad. Sci. USA 88, 8227-8231; Cooney et al., (1988) Science 241, 456-459; Young et al., (1991) Proc. Natl. Acad. Sci. USA 88, 10023-10026; Duval-Valentin et al., (1992) Proc. Natl. Acad. Sci. USA 89, 504-508; Blume et al., (1992) Nucl. Acids Res. 20, 1777-1784; Grigoriev et al., (1992) J. Biol. Chem. 267, 3389-3395.

Recently, both theoretical calculations and empirical findings have been reported which provide guidance for the design of oligonucleotides for use in oligonucleotide-directed triple helix formation to inhibit gene expression. For example, oligonucleotides should generally be greater than 14 nucleotides in length to ensure target sequence specificity (see, e.g., Maher et al., (1989); Grigoriev et al., (1992)). Also, many cells avidly take up oligonucleotides that are less than 50 nucleotides in length (see e.g., Orson et al., (1991); Holt et al., (1988) Mol. Cell. Biol. 8, 963-973; Wickstrom et al., (1988) Proc. Natl. Acad. Sci. USA 85, 1028-1032). To reduce susceptibility to intracellular degradation, for example by 3' exonucleases, a free amine can be introduced to a 3'

5 terminal hydroxyl group of oligonucleotides without loss of sequence binding specificity (Orson et al., 1991). Furthermore, more stable triplexes are formed if any cytosines that may be present in the oligonucleotide are methylated, and also if an intercalating agent, such as an acridine derivative, is covalently attached to a 5' terminal phosphate (e.g., via a pentamethylene bridge); again without loss of sequence specificity (Maher et al., (1989);  
10 Grigoriev et al., (1992).

15 Methods to produce or synthesize oligonucleotides are well known in the art. Such methods can range from standard enzymatic digestion followed by nucleotide fragment isolation (see e.g., Sambrook et al., Chapters 5, 6) to purely synthetic methods, for example, by the cyanoethyl phosphoramidite method using a Milligen or Beckman System 1Plus DNA synthesizer (see also, Ikuta et al., (1984) Ann. Rev. Biochem. 53, 323-356 (phosphotriester and phosphite-triester methods); Narang et al., (1980)  
20 Methods Enzymol., 65, 610-620 (phosphotriester method)). Accordingly, DNA sequences of the 5' flanking region of the receptor protein gene described herein can be used to design and construct  
25 oligonucleotides including a DNA sequence consisting essentially of at least 15 consecutive nucleotides, with or without base modifications or intercalating agent derivatives, for use in forming triple helices specifically within the 5' flanking region of a  
30 receptor protein gene in order to inhibit expression of the gene.

35 In some cases it may be advantageous to insert enhancers or multiple copies of the regulatory sequences into an expression system to facilitate screening of methods and reagents for manipulation of

expression.

*Preparation of Receptor Protein Fragments*

Compounds which are effective for blocking binding of the receptor can also consist of fragments of the receptor proteins, expressed recombinantly and cleaved by enzymatic digest or expressed from a sequence encoding a peptide of less than the full length receptor protein. These will typically be soluble proteins, i.e., not including the transmembrane and cytoplasmic regions, although smaller portions determined in the assays described above to inhibit or compete for binding to the receptor proteins can also be utilized. It is a routine matter to make appropriate receptor protein fragments, test for binding, and then utilize. The preferred fragments are of human origin, in order to minimize potential immunological response. The peptides can be as short as five to eight amino acids in length and are easily prepared by standard techniques. They can also be modified to increase *in vivo* half-life, by chemical modification of the amino acids or by attachment to a carrier molecule or inert substrate. Based on studies with other peptide fragments blocking receptor binding, the IC<sub>50</sub>, the dose of peptide required to inhibit binding by 50%, ranges from about 1 μM to greater than 10 mM, depending on the peptide size and folding. These ranges are well within the effective concentrations for the *in vivo* administration of peptides, based on comparison with the RGD-containing peptides, described, for example, in U.S. Patent No. 4,792,525 to Ruoslahti, et al., used *in vivo* to alter cell attachment and phagocytosis. The peptides can also be conjugated to a carrier protein such as keyhole limpet hemocyanin by

its N-terminal cysteine by standard procedures such as the commercial Imject kit from Pierce Chemicals or expressed as a fusion protein, which may have increased efficacy.

5 As noted above, the peptides can be prepared by proteolytic cleavage of the receptor proteins, or, preferably, by synthetic means. These methods are known to those skilled in the art. An example is the solid phase synthesis described by J. Merrifield, 10 (1964) J. Am. Chem. Soc. 85, 2149, used in U.S. Patent No. 4,792,525, and described in U.S. Patent No.

15 4,244,946, wherein a protected alpha-amino acid is coupled to a suitable resin, to initiate synthesis of a peptide starting from the C-terminus of the peptide. Other methods of synthesis are described in U.S. 20 Patent No. 4,305,872 and 4,316,891. These methods can be used to synthesize peptides having identical sequence to the receptor proteins described herein, or substitutions or additions of amino acids, which can be screened for activity as described above.

25 The peptide can also be administered as a pharmaceutically acceptable acid- or base- addition salt, formed by reaction with inorganic acids such as hydrochloric acid, hydrobromic acid, perchloric acid, nitric acid, thiocyanic acid, sulfuric acid, and phosphoric acid, and organic acids such as formic acid, acetic acid, propionic acid, glycolic acid, lactic acid, pyruvic acid, oxalic acid, malonic acid, succinic acid, maleic acid, and fumaric acid, or by 30 reaction with an inorganic base such as sodium hydroxide, ammonium hydroxide, potassium hydroxide, and organic bases such as mono-, di-, trialkyl and aryl amines and substituted ethanolamines.

35 Peptides containing cyclopropyl amino acids, or amino acids derivatized in a similar fashion, can

also be used. These peptides retain their original activity but have increased half-lives *in vivo*.  
Methods known for modifying amino acids, and their  
use, are known to those skilled in the art, for  
example, as described in U.S. Patent No. 4,629,784 to  
5 Stammer.

The peptides are generally active when administered parenterally in amounts above about 1  $\mu\text{g}/\text{kg}$  of body weight. Based on extrapolation from other proteins, for treatment of most inflammatory disorders, the dosage range will be between 0.1 to 70 mg/kg of body weight. This dosage will be dependent, in part, on whether one or more peptides are administered.  
10

#### 15 *Pharmaceutical Compositions*

Compounds which alter receptor protein binding are preferably administered in a pharmaceutically acceptable vehicle. Suitable pharmaceutical vehicles are known to those skilled in the art. For parenteral administration, the compound will usually be dissolved or suspended in sterile water or saline. For enteral administration, the compound will be incorporated into an inert carrier in tablet, liquid, or capsular form. Suitable carriers may be starches or sugars and include lubricants, flavorings, binders, and other materials of the same nature. The compounds can also be administered locally by topical application of a solution, cream, gel, or polymeric material (for example, a Pluronic<sup>TM</sup>, BASF).  
20  
25  
30

Alternatively, the compound may be administered in liposomes or microspheres (or microparticles). Methods for preparing liposomes and microspheres for administration to a patient are known

to those skilled in the art. U.S. Patent No. 4,789,734 describe methods for encapsulating biological materials in liposomes. Essentially, the material is dissolved in an aqueous solution, the appropriate phospholipids and lipids added, along with surfactants if required, and the material dialyzed or sonicated, as necessary. A review of known methods is by G. Gregoriadis, Chapter 14. "Liposomes", Drug Carriers in Biology and Medicine pp. 287-341 (Academic Press, 1979). Microspheres formed of polymers or proteins are well known to those skilled in the art, and can be tailored for passage through the gastrointestinal tract directly into the bloodstream. Alternatively, the compound can be incorporated and the microspheres, or composite of microspheres, implanted for slow release over a period of time, ranging from days to months. See, for example, U.S. Patent Nos. 4,906,474, 4,925,673, and 3,625,214.

*Disorders to be treated*

As described herein, a variety of compounds can be used to inhibit or enhance expression of the EPCR. The nature of the disorder will determine if the expression should be enhanced or inhibited. For example, based on the studies involving the use of an anti-protein C antibody in combination with cytokine, it should be possible to treat solid tumors by enhancing an inflammatory response involving blocking of protein C or activated protein C binding to an endothelial cell protein C/activated protein C receptor by administering to a patient in need of treatment thereof an amount of a compound blocking binding of protein C or activated protein C to the receptor. Similarly, it should be possible to treat disorders such as gram negative sepsis, stroke, thrombosis, septic shock, adult respiratory distress

syndrome, and pulmonary emboli using a method for inhibiting an inflammatory response involving administration of EPCR or EPCR fragments or substances that upregulate EPCR expression to a patient in need of treatment therof.

Modifications and variations of the methods and materials described herein will be obvious to those skilled in the art and are intended to be encompassed by the following claims. The teachings of the references cited herein are specifically incorporated herein. -

10

## SEQUENCE LISTING

## (1) GENERAL INFORMATION:

(i) APPLICANT: Fukudome, Kenji  
Esmon, Charles T.

(ii) TITLE OF INVENTION: Cloning and Regulation of an Endothelial Cell Protein C/Activated Protein C Receptor

(iii) NUMBER OF SEQUENCES: 2

(iv) CORRESPONDENCE ADDRESS:  
(A) ADDRESSEE: Patrea L. Pabst  
(B) STREET: 1100 Peachtree Street, Suite 2800  
(C) CITY: Atlanta  
(D) STATE: Georgia  
(E) COUNTRY: USA  
(F) ZIP: 30309-4530

(v) COMPUTER READABLE FORM:  
(A) MEDIUM TYPE: Floppy disk  
(B) COMPUTER: IBM PC compatible  
(C) OPERATING SYSTEM: PC-DOS/MS-DOS  
(D) SOFTWARE: PatentIn Release #1.0, Version #1.25

(vi) ATTORNEY/AGENT INFORMATION:  
(A) NAME: Patrea L.  
(B) REGISTRATION NUMBER: 31,284  
(C) REFERENCE/DOCKET NUMBER: OMRF152

(ix) TELECOMMUNICATION INFORMATION:  
(A) TELEPHONE: (404) 815-6508  
(B) TELEFAX: (404) 815-6555

(2) INFORMATION FOR SEQ ID NO:1:

(i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 1302 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA  
(iii) HYPOTHETICAL: NO  
(iv) ANTI-SENSE: NO

(ix) FEATURE:  
(A) NAME/KEY: misc\_feature

(B) LOCATION: 1..1302  
 (D) OTHER INFORMATION: /note= "Nucleotides 25 through 738 encode the  
 Endothelial Cell Protein Receptor of Sequence ID No. 2."  
 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

CAGGTCGGGA	GCCTCAACTT	CAGGATGTTG	ACAAACATTRGC	TGCCGATACT	GCTGGCTGTCT	60
GGCTGGCCT	TTTGTAGCCA	AGACGCCCTCA	GATGGCCCTCC	AAAGACTTCA	TATGGCTCCAG	120
ATCTCTACT	TCCGGACCC	CTATCACGTG	TGGTACCAGG	GCAACGGGTC	GCTGGGGGA	180
CACCTAACGC	ACGTGCTGGA	AGGCCAGAC	ACCAACACCA	CGATCATTC	GCTGGCAGCCC	240
TTGCAGGAGC	CCGAGAGCTG	GGCGCGCAGG	CAGAGTGGCC	TGCAGTCCTA	CCTGCTCCAG	300
TTCCACGGCC	TGTTGGCCCT	GGTGCACAG	GAGGGACCT	TGGCCTTTC	TCTGACCATC	360
CGCTGCTCC	TGGGCTGTCA	GCTGCCCTCCC	GAGGGCTCTA	GAGCCCCATGT	CTTCTTCGAA	420
GTGGCTGTGA	ATGGGAGCTC	CTTGTGAGT	TTCCGGCCGG	AGAGAGCCTT	GTGGCAGGCA	480
GACACCCAGG	TCACCTCCGG	AGTGGTCACC	TTCACCCCTGC	AGCAGCTCAA	TGCCTACAC	540
CGCACTCGGT	ATGAAC TGCG	GGAAATTCTCTG	GAGGACACCT	GTGTGCCAGTA	TGTGCAGAAA	600
CATATTCGG	CGGAAAAACAC	AAAAGGGAGC	CAAACAAGCC	GCTCCTACAC	TTCGCTGGTC	660
CTGGCGTCC	TGGTGGCCGG	TTTCATCATT	GCTGGTGTGG	CTGTAGGCA	CTTCCCTGTGC	720
ACAGGGAC	GGCGATGTTA	ATTACTCTCC	AGCTCACTGT	GAAGCCAGAC	TCCCAAACTG	780
GGCTGGCAAG	GGAAAGTTTC	GGCTGGCAAG	GGCTGGCAAG	GGCTGGCAAG	AAACACCAAGA	840
AGGTTGGAG	TGACAGCTCC	TTTCTCTCC	CACATCTGCC	CACTGAAGAT	TTGAGGGAGG	900
GGAGATGGAG	AGGAGAGCTG	GACAAAGTAC	TGGTTTGCT	AGAACCTAA	GAACGTGTAT	960

GCTTGTGCTGA ATTAGTCTGA TAAGTGAATG TTATCTATC TTGTGGAAA ACAGATAATG 1020  
 GAGTTGGGC AGGAAGCCTA TGGCCATCC TCCAAGACA GACAGAAATCA CCTGAGGGGT 1080  
 TCAAAGATA TAACCAAATA ACAAGTCAT CCACAATCAA AATACAAACAT TCAATACTTC 1140  
 CAGGTGTGTC AGACTTGGGA TGGGACCGCTG ATATAATTAGG GTAGAAAGAA GTAACACGAA 1200  
 GAAGTGGTGG AAATGTAAAA TCCAAGTCAT ATGGCAGTGA TCAATTATA ATCAAATTAAAT 1260  
 AATATTAATA ATTTCCTTAT ATTAAAAAA AAAAAGAAAA AA 1302

## (2) INFORMATION FOR SEQ ID NO:2:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 238 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein
- (iii) HYPOTHETICAL: NO
- (ix) FEATURE:

(A) NAME/KEY: misc\_feature

(B) LOCATION: 1..365

(D) OTHER INFORMATION: /note= "Endothelial Cell Protein Receptor encoded by nucleotides 1 through 1302 of Sequence ID No. 1."

## (ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: 1..15
- (D) OTHER INFORMATION: /note= "Amino acids 1-15 represent a putative signal sequence."

## (ix) FEATURE:

- (A) NAME/KEY: Domain
- (B) LOCATION: 211..236
- (D) OTHER INFORMATION: /note= "Amino acids 211-236 represent a putative transmembrane domain."

## (ix) FEATURE:

- (A) NAME/KEY: Active-site
- (B) LOCATION: 47..174

(D) OTHER INFORMATION: /note= "Amino acids 47-49, 64-66, 136-138 and 172-174 represent potential N-glycosylation sites."

(ix) FEATURE:  
(A) NAME/KEY: Modified-site  
(B) LOCATION: 17..186  
(C) OTHER INFORMATION: /note= "Amino acids 17, 114, 118  
and 186 represent extracellular cysteine

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2:  
residues."

41

Pro	Glu	Arg	Ala	Leu	Trp	Gln	Ala	Asp	Thr	Gln	Val	Thr	Ser	Gly	Val
145										155					160
Val	Thr	Phe	Thr	Leu	Gln	Gln	Leu	Asn	Ala	Tyr	Asn	Arg	Thr	Arg	Tyr
		165						170						175	
Glu	Leu	Arg	Glu	Phe	Leu	Glu	Asp	Thr	Cys	Val	Gln	Tyr	Val	Gln	Lys
		180						185					190		
His	Ile	Ser	Ala	Glu	Asn	Thr	Lys	Gly	Ser	Gln	Thr	Ser	Arg	Ser	Tyr
		195				200					205				
Thr	Ser	Leu	Val	Leu	Gly	Val	Leu	Val	Gly	Gly	Phe	Ile	Ile	Ala	Gly
		210				215					220				
Val	Ala	Val	Gly	Ile	Phe	Leu	Cys	Thr	Gly	Gly	Arg	Arg	Cys		
		225				230					235				

We claim.

1. An isolated endothelial cell protein C/activated protein C receptor.

2. The receptor of claim 1 encoded by the nucleotide sequence of Sequence ID No. 1 and degenerative sequences thereof and sequence having conservative substitutions, additions or deletions thereof hybridizing to Sequence ID No. 1 under stringent conditions, which encode the receptor.

3. The receptor of claim 1 having the amino acid sequence of Sequence ID No. 2 or a sequence having conservative substitutions, additions or deletions thereof.

4. The receptor of claim 1 expressed on the surface of a non-human cell or a non-endothelial cell.

5. The receptor of claim 1 in soluble form.

6. The receptor of claim 5 lacking at least a portion of the transmembrane region.

7. A nucleotide sequence encoding an endothelial cell protein C/activated protein C receptor.

8. The sequence of claim 7 having the nucleotide sequence of Sequence ID No. 1 or degenerative sequences thereof and sequence having conservative substitutions, additions or deletions thereof and hybridizing under stringent conditions to Sequence ID No. 1.

9. The sequence of claim 7 encoding the amino acid sequence of Sequence ID No. 2 or a sequence having conservative substitutions, additions or deletions thereof.

10. The sequence of claim 7 further comprising an expression vector.

11. The sequence of claim 10 further comprising an expression host.

12. The sequence of claim 10 expressed on the surface of a non-human cell or a non-endothelial cell.

13. The sequence of claim 7 encoding a soluble form of the receptor.

14. The sequence of claim 7 encoding a fragment of the receptor of at least fourteen consecutive nucleotides in length.

15. The sequence of claim 14 labelled with a detectable label.

16. A method for enhancing an inflammatory response involving blocking of protein C or activated protein C binding to an endothelial cell protein C/activated protein C receptor comprising administering to a patient in need of treatment thereof an amount of a compound blocking binding of protein C or activated protein C to the receptor. tumors

17. The method of claim 16 wherein the compound is selected from the group consisting of antibodies and fragments of antibodies to the receptor, nucleic acid sequences inhibiting expression of the receptor, and synthetic or natural compounds other than proteins, peptides or nucleic acid sequences which inhibit binding.

18. A method for inhibiting an inflammatory response involving administration of a compound selected from the group consisting of EPCR or EPCR fragments and substances that upregulate EPCR expression to a patient in need of treatment therof.

19. An antibody or antibody fragment specifically immunoreactive with a unique epitope of an isolated endothelial cell protein C/activated protein C receptor.

20. The antibody of claim 19 wherein the

receptor is encoded by the nucleotide sequence of Sequence ID No. 1 and degenerative sequences thereof and sequence having conservative substitutions, additions or deletions thereof and hybridizing to Sequence ID No. 1 under stringent conditions.

21. The antibody of claim 19 wherein the receptor has the amino acid sequence of Sequence ID No. 2 or a sequence having conservative substitutions, additions or deletions thereof.

22. A method for screening for a compound which alters the binding of an endothelial receptor protein to protein C or activated protein C comprising providing an assay for binding of protein C or activated protein C to the receptor protein, adding the compound to be tested to the assay, and

determining if the amount of protein C or activated protein C which is bound to the receptor protein is altered as compared to binding in the absence of the compound to be tested.

23. A method for screening patients for abnormal receptor protein activity or function comprising

determining the presence of an endothelial cell surface receptor binding protein C and activated protein C, and

comparing the receptor to determine if the quantity present or the function of the receptor is equivalent to that present in normal cells.

CLONING AND REGULATION OF AN ENDOTHELIAL CELL  
PROTEIN C/ACTIVATED PROTEIN C RECEPTOR

Abstract of the Invention

Human protein C and activated protein C were shown to bind to endothelium specifically, selectively and saturably ( $K_d=30$  nM, 7000 sites per cell) in a  $\text{Ca}^{2+}$  dependent fashion. Expression cloning revealed a 1.3 kb cDNA that coded for a novel type I transmembrane glycoprotein capable of binding protein C. This protein appears to be a member of the CD1/MHC superfamily. Like thrombomodulin, the receptor involved in protein C activation, the endothelial cell protein C receptor (EPCR) function and message are both down regulated by exposure of endothelium to TNF. Identification of EPCR as a member of the CD1/MHC superfamily provides insights into the role of protein C in regulating the inflammatory response, and determination of methods for pharmaceutical use in manipulating the inflammatory response.




FIG. 1a




FIG. 1b




FIG. 1c




FIG. 2a




FIG. 2b




FIG. 2c




FIG. 2d




FIG. 3a




FIG. 3b

F/G. 4<sup>a</sup>  
CAGGTCCGGAGCCTCAACTCAGGATGGTGGACAAACATTGCTCAGATGGCCTCAGATGGCTCAAAGAACCTCATATGCTCCAG 60  
M L T T L P I L L S  
G W A F C S Q D A S D G L Q R L H W L Q 32

GGCTGGGCCCTTTGAGCCAAGACCCCTATGACCGTGTGGTACCCAGGGCAACGGCGTCGCTGGGGGA 120  
ATCTCTACTTCCCCGACCCCTATGACCGTGTGGTACCCAGGGCAACGGCGTCGCTGGGGGA 180  
I S Y F R D P Y H V W Y Q G N A S L G G 52

CACCTAACGGCACGTGTGGAGGGCCAGAACCAACGATCATTGAGCTGGCAGGCC 240  
H L T H V L E G P D T N T T I I Q L Q P 72

TTGGAGGGAGAGCTGGGGCGCACGGAGACTGGCCTGCACTGCCTACCTGGCTCCAG 300  
L Q E P E S W A R T Q S G L Q S Y L L Q 92

TTCCACGGCCTCGTGGCCTGGTGCACCGAGGGACCTGGCCCTTCCTGACCATC 360  
F H G L V R L V H Q E R T L A F P L T I 112

CGCTGCTTCCTGGGCTGTGAGGCTGCTCCCAGGGCTCTAGAGCCCATGTCCTTCGAA 420  
R C F L G C E L P P E G S R A H V F F E 132

FIG. 4b

GTCGGCTGTGAATGGGAGGCTCCTTGTGAGTTTCCGGAGAGGCCCTTGTGGCAGGCA 480  
V A V N G S S F V S F R P E R A L W Q A 152

GACACCCAGGTCACCTCCGGAGGTGGTCACCTTCACCCCTGCAGCAGGCTCAATGCCTACAAC 540  
D T Q V T S G V V T F T L Q Q L N A Y N 172

CGCACTCGGTATGAACTGGGGAAATTCTGGAGGACACCTGTGTGCAGTATGTGCAGAAA 600  
R T R Y E L R E F L E D T C V Q Y V Q K 192

CATATTTCCGGGAAACACGAAAGGGAGGCCAACAAAGCCGCTCCTACACTCGCTGGTC 660  
H I S A E N T K G S Q T S R S Y T S L V 212

CTGGGGCCTGGTGGCTCATCATTCATTGCTGGCTGTAGGCATCTTCCTGTGC 720  
L G V L V G G F I I A G V A V G I F L C 232

ACAGGGTGGACGGCGATGTTAATTACTCTCCAGCCCCGTCAAGAAGGGGGCTGGATTGATGGA 780  
T G G R R C \* 238

560 280 190 100 50

F/G. 4c

GGCTGGCAAGGAAAGTTTCAAGCTCACTGTGAAGCCAGACTCCCCAACTGAAACACAGA 840  
AGTTTGAGTGCACAGCCTCTTCTCCCACATCTGCCACTGAAAGATTGAGGGAGG 900  
GGAGATGGAGGGAGGTGGACAAGTACTTGGTTGCTAAGAACCTAAGAACGTTAT 960  
GCCTTGCTGAATTAGTCATAAGTGAATGTTATCTATCTTGTGGAAAACAGATAATG 1020  
GAGTTGGGGCAGGAAGCCTATGCCCATCCTCCAAAGACAGACAGAATCACCTGAGGCGT 1080  
TCAAAGATAACCAAAATAAACAAAGTCATCCACAATCAAATCAAACATTCAACTTC 1140  
CAGGTGTGTCAAGACTTGGGATGGGACGGCTGATAATAAGGTAGAAAGTAACACGAA 1200  
GAAGTGGTGGAAATGTAATCCAAGTCATGGCAGTGTGATCAAATTAAATCAAATTAAAT 1260  
AATATTAAATAATTCTTATTTAAATTTAAAAAA 1302




FIG. 5a

C. M. C. S. J. C. B.

<b>EPCR</b> <b>CCD41</b> <b>CD1d</b> <b>MCD1.2</b>	<b>MLTT</b> <b>MLTKF</b> <b>MGC</b> <b>MRY</b>	<b>MLTTFCSODASDGQRHMQISYFRDHYHVWYQGNASLGGHLTHV</b> <b>FPRPSCEASGRSLGKLTHTL</b> <b>FPRPSCEASGRSLGKLTHTL</b> <b>FPRPSCEASGRSLGKLTHTL</b>	<b>MLTTFCSODASDGQRHMQISYFRDHYHVWYQGNASLGGHLTHV</b> <b>FPRPSCEASGRSLGKLTHTL</b> <b>FPRPSCEASGRSLGKLTHTL</b> <b>FPRPSCEASGRSLGKLTHTL</b>	<b>MLTTFCSODASDGQRHMQISYFRDHYHVWYQGNASLGGHLTHV</b> <b>FPRPSCEASGRSLGKLTHTL</b> <b>FPRPSCEASGRSLGKLTHTL</b> <b>FPRPSCEASGRSLGKLTHTL</b>
<b>EPCR</b> <b>CCD41</b> <b>CD1d</b> <b>MCD1.2</b>	<b>EGPDNTITIQLQPQEPESWARTQSGLQSYLQFHGLVRLVH</b> <b>EGPSQAVTILQLQPWQDPESWERTESGLQIYLTQFESLVK</b> <b>DSDTVRSIKPWSQGTFSDQQWETLQHIFRVYRSSFTRDVK</b> <b>DSATISFTKPKWSQGKLSNQQWEKLQHELVKMMSPKEDYPTET</b>	<b>EGPDNTITIQLQPQEPESWARTQSGLQSYLQFHGLVRLVH</b> <b>EGPSQAVTILQLQPWQDPESWERTESGLQIYLTQFESLVK</b> <b>DSDTVRSIKPWSQGTFSDQQWETLQHIFRVYRSSFTRDVK</b> <b>DSATISFTKPKWSQGKLSNQQWEKLQHELVKMMSPKEDYPTET</b>	<b>EGPDNTITIQLQPQEPESWARTQSGLQSYLQFHGLVRLVH</b> <b>EGPSQAVTILQLQPWQDPESWERTESGLQIYLTQFESLVK</b> <b>DSDTVRSIKPWSQGTFSDQQWETLQHIFRVYRSSFTRDVK</b> <b>DSATISFTKPKWSQGKLSNQQWEKLQHELVKMMSPKEDYPTET</b>	<b>EGPDNTITIQLQPQEPESWARTQSGLQSYLQFHGLVRLVH</b> <b>EGPSQAVTILQLQPWQDPESWERTESGLQIYLTQFESLVK</b> <b>DSDTVRSIKPWSQGTFSDQQWETLQHIFRVYRSSFTRDVK</b> <b>DSATISFTKPKWSQGKLSNQQWEKLQHELVKMMSPKEDYPTET</b>
<b>EPCR</b> <b>CCD41</b> <b>CD1d</b> <b>MCD1.2</b>	<b>RCFLGCEL.P...PEGSRAHVFFEEAVNGSSFVSFRPERALWQADTQVTSGVVTFTLQQQ</b> <b>SCSAGCEL.PEEEEGSEPHVFFDVAVNGSAFVSFRPKTAWVSGSQEPSSKAANFTL</b> <b>QVSAGCEVHP....GNASNNFFHWAFOGKDILSFQGTS.TEAPLWVNLAIVV</b> <b>QLSTGCEMYP....GNASESEFFHWAFOGKYAVRFRGTS.WQR.VLGAPSWLDPIKV</b>	<b>RCFLGCEL.P...PEGSRAHVFFEEAVNGSSFVSFRPERALWQADTQVTSGVVTFTLQQQ</b> <b>SCSAGCEL.PEEEEGSEPHVFFDVAVNGSAFVSFRPKTAWVSGSQEPSSKAANFTL</b> <b>QVSAGCEVHP....GNASNNFFHWAFOGKDILSFQGTS.TEAPLWVNLAIVV</b> <b>QLSTGCEMYP....GNASESEFFHWAFOGKYAVRFRGTS.WQR.VLGAPSWLDPIKV</b>	<b>RCFLGCEL.P...PEGSRAHVFFEEAVNGSSFVSFRPERALWQADTQVTSGVVTFTLQQQ</b> <b>SCSAGCEL.PEEEEGSEPHVFFDVAVNGSAFVSFRPKTAWVSGSQEPSSKAANFTL</b> <b>QVSAGCEVHP....GNASNNFFHWAFOGKDILSFQGTS.TEAPLWVNLAIVV</b> <b>QLSTGCEMYP....GNASESEFFHWAFOGKYAVRFRGTS.WQR.VLGAPSWLDPIKV</b>	<b>RCFLGCEL.P...PEGSRAHVFFEEAVNGSSFVSFRPERALWQADTQVTSGVVTFTLQQQ</b> <b>SCSAGCEL.PEEEEGSEPHVFFDVAVNGSAFVSFRPKTAWVSGSQEPSSKAANFTL</b> <b>QVSAGCEVHP....GNASNNFFHWAFOGKDILSFQGTS.TEAPLWVNLAIVV</b> <b>QLSTGCEMYP....GNASESEFFHWAFOGKYAVRFRGTS.WQR.VLGAPSWLDPIKV</b>

FIG. 5b

EPCR	NAYNRTRYELREFILEDTCVQYV	QKHTSAENTKGSQT[S]
CCD41	NAYNRTRYELQDTCVEFL	ENHITTQN[M]KGSQT[G]
CD1d	NQDKWTRETVQWLNGT[CPQF]	SPGPGRLLLVC[V]SG
MCD1.2	NADQGTISATVQTLNDTWPQF	SAHGHQLQLVCH[V]SG

EPCR	RSYTSVLGVVGGFTIAGVAVGIFCTGGRRC
CCD41	RSYTSVLGVLMGCFTIAGVAVGIFMCTSGRLII
CD1d	DIVLYWGGSYTSMGLTAALAVLACLLFLIVGFTS.RFKRQTSYQGVVL
MCD1.2	QDILYWNDARQAPVGIVFIVLIMLVVGAVVYYI.WRRRSAYQDIR

De 1908 x. - 1909  
1908 (2) 1909 (3)

1 MLTLLP..ILLSGWAFCSQDASDGLQRLHMLQISYFRDPYHVWYQGNA48  
|||:|| :|||-|||.|||||.|||||||.|||:|||||  
1 MLTKFLPLLLLLPGCALCN...SDGSOSLHMLQISYFQDHHHVRHQGNA 47

49 SLGGHLTHVLEG PDTNTTIIQLQPLQE PESWARTQSGLQS YLLQFHGLVR 98  
||| ||||| .|||:|||:|||:|||:|||:|||:|||:|||:|||:|||:  
48 SLGKLLHTL TLEGPSQNVTIQLQPWQDPESWERTESGLQIYL TQFESLVK 97

99 LVHQER..TLA FPLTIRCFLGCELP...PEG SRAH VFFEVAVNGSSFVSF 143  
|||:|| .:|||:|||:|||:|||:|||:|||:|||:|||:  
98 LVYRERKENVFFFPLTVSCSLGCELPEEEEGSEPHVFFDVAVNGSAFVSF 147

144 RPERALWQADTQVTSGVVTFTLQQLNAYNRTRYELREFLEDTCVQYVQKH193  
|||:|||:|||:|||:|||:|||:|||:|||:|||:|||:  
148 RPKTAVWVSGSQEPSKAANFTLKQLNAYNRTRYELQEFLQDTCVEFLENH 197

194 ISAENTKGSQTRSYTSVLGVLVGGFIAGVAVGIFLCTGGRRRC 238  
|||:|||:|||:|||:|||:|||:|||:|||:  
198 ITTQN MKGSQTGRSYTSVLGILMGCFIAGVAVGIFMCTS GRRC 242

FIG. 6

DECLARATION FOR PATENT APPLICATION

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name;

I believe I am the original, first and sole inventor (if only one name is listed below), or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

**"Cloning and Regulation of an Endothelial Cell  
Protein C/Activated Protein C Receptor"**

the specification of which (check one)

is attached hereto

was filed on \_\_\_\_\_  
as application Serial No. \_\_\_\_\_

and was amended on: \_\_\_\_\_  
(if applicable)

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to the examination of this application in accordance with Title 37, Code of Federal Regulations, § 1.56(a).

I hereby claim foreign priority benefits under Title 35, United States Code, § 119 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed.

Prior Foreign Application(s)			<u>Priority Claimed</u>
(Number)	(Country)	(Day/Month/Year Filed)	
(Number)	(Country)	(Day/Month/Year Filed)	

I hereby claim the benefit under Title 35, United States Code, § 120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of the application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, § 112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, § 1.56(a) which occurred between the filing date of the prior application and the national or PCT international filing date of this application:

(Application Serial No.)	(Filing Date)	Status (patented, pending, abandoned)

"Cloning and Regulation of an Endothelial Cell  
Protein C/Activated Protein C Receptor"  
Filed: August 12, 1994  
By: Kenji Fukudome and Charles T. Esmon  
DECLARATION FOR PATENT APPLICATION

As named inventor, I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and transact all business in the Patent and Trademark Office connected therewith.

John S. Pratt	29,476
James L. Ewing, IV	30,630
Patrea L. Pabst	31,284
Cheryl K. Zalesky	33,052
Dean W. Russell	33,452
Jamie L. Greene	32,467
Claudia R. Adkison	36,979
David S. Bradin	37,783
Craig R. Kaufman	34,636
Felipe J. Farley	P-38,445

Send Correspondence to: Patrea L. Pabst, Esq.  
Kilpatrick & Cody  
1100 Peachtree Street, Suite 2800  
Atlanta, Georgia 30309-4530

Direct telephone calls to: Patrea L. Pabst (404) 815-6508

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full name of sole or first inventor Kenji Fukudome

Inventor's signature \_\_\_\_\_ Date \_\_\_\_\_

Residence 13125 West Park Place, Oklahoma City, Oklahoma 73142

Citizenship Japan

Post Office Address Same as above

Full name of second joint inventor (if any) Charles T. Esmon

Inventor's signature \_\_\_\_\_ Date \_\_\_\_\_

Residence 5800 North Stonewall, Oklahoma City, Oklahoma 73111

Citizenship U.S.A.

Post Office Address Same as above

DECLARATION FOR PATENT APPLICATION

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name;

I believe I am the original, first and sole inventor (if only one name is listed below), or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

**"Cloning and Regulation of an Endothelial Cell  
Protein C/Activated Protein C Receptor"**

the specification of which (check one)

is attached hereto

was filed on August 12, 1994  
as application Serial No. 08/289,699

and was amended on: \_\_\_\_\_  
(if applicable)

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to the examination of this application in accordance with Title 37, Code of Federal Regulations, § 1.56(a).

I hereby claim foreign priority benefits under Title 35, United States Code, § 119 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed.

Prior Foreign Application(s)	Priority Claimed
(Number)	(Country)
(Number)	(Country)
(Number)	(Country)

I hereby claim the benefit under Title 35, United States Code, § 120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of the application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, § 112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, § 1.56(a) which occurred between the filing date of the prior application and the national or PCT international filing date of this application:

(Application Serial No.)	(Filing Date)	Status (patented, pending, abandoned)
(Application Serial No.)	(Filing Date)	Status (patented, pending, abandoned)

U.S.S.N. 08/289,699

Filed: August 12, 1994

By: Kenji Fukudome and Charles T. Esmon

DECLARATION FOR PATENT APPLICATION

As named inventor, I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and transact all business in the Patent and Trademark Office connected therewith.

John S. Pratt	29,476
James L. Ewing, IV	30,630
Patrea L. Pabst	31,284
Cheryl K. Zalesky	33,052
Dean W. Russell	33,452
Jamie L. Greene	32,467
Claudia R. Adkison	36,979
David S. Bradin	37,783
Craig R. Kaufman	34,636
Felipe J. Farley	P-38,445

Send Correspondence to: Patrea L. Pabst, Esq.  
Kilpatrick & Cody  
1100 Peachtree Street, Suite 2800  
Atlanta, Georgia 30309-4530

Direct telephone calls to: Patrea L. Pabst (404) 815-6508

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full name of sole or first inventor Kenji Fukudome

Inventor's signature Kenji Fukudome

Date 9/28/94

Residence 13125 West Park Place, Oklahoma City, Oklahoma 73142

Citizenship Japan

Post Office Address Same as above

Full name of second joint inventor (if any) Charles T. Esmon

Inventor's signature Charles T. Esmon

Date 9/28/94

Residence 5800 North Stonewall, Oklahoma City, Oklahoma 73111

Citizenship U.S.A.

Post Office Address Same as above

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Kenji Fukudome and Charles T. Esmon

Express Mail Label No.:  
EL 273 004 882 US

Serial No.: Divisional of 09/182,616

Group Art Unit: Not Yet Assigned

Filed: August 20, 1999

Examiner: Not Yet Assigned

For: *CLONING AND REGULATION OF AN ENDOTHELIAL CELL PROTEIN  
C/ACTIVATED PROTEIN C RECEPTOR*

Assistant Commissioner for Patents  
Washington, D.C. 20231

**ASSOCIATE POWER OF ATTORNEY UNDER 37 C.F.R. § 1.34**


Sir:

Please recognize as Associate Patent Attorneys and Patent Agent in this case:

Robert A. Hodges      Reg. No. 41,074  
Kevin W. King      Reg. No. 42,737

Please continue to direct all communication to Patrea Pabst at the following address:

**Patrea L. Pabst, Esq.**  
**ARNALL GOLDEN & GREGORY, LLP**  
**2800 One Atlantic Center**  
**1201 West Peachtree Street**  
**Atlanta, Georgia 30309-3450**  
**(404) 873-8794; 873-8795 (fax)**

  
\_\_\_\_\_  
Patrea L. Pabst, Reg. No. 31,284

Date: August 20, 1999

ARNALL GOLDEN & GREGORY, LLP  
2800 One Atlantic Center  
1201 West Peachtree Street  
Atlanta, Georgia 30309-3450  
(404) 873-8794  
(404) 873-8595 (fax)

OMRF 152 DIV(3)  
20487/242

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Kenji Fukudome and Charles T. Esmon

Serial No.: 08/289,699 Art Unit: 1812

Filed: August 12, 1994 Examiner: S. Gucker

For: CLONING AND REGULATION OF AN ENDOTHELIAL CELL  
PROTEIN C/ACTIVATED PROTEIN C RECEPTOR

Commissioner of Patents  
and Trademarks  
Washington, D. C. 20231

**POWER OF ATTORNEY BY ASSIGNEE OF ENTIRE INTEREST  
AND REVOCATION OF PRIOR POWERS**

Sir:

As owner of entire interest in the above-identified patent application, all powers of attorney previously given are hereby revoked and the following attorneys are hereby appointed to prosecute and transact all business in the Patent and Trademark Office connected therewith:

Patrea L. Pabst	Registration No. 31,284
Madeline I. Johnston	Registration No. 36,174
Dolly A. Vance	Registration No. 39,054

Please send all correspondence relating to the above patent application to:

Patrea L. Pabst  
ARNALL GOLDEN & GREGORY  
2800 One Atlantic Center  
1201 West Peachtree Street  
Atlanta, Georgia 30309-3450

(404) 873-8794 - Telephone  
(404) 873-8795 - Telefax

U.S.S.N. 08/289,699

Filed: August 12, 1994

POWER OF ATTORNEY BY ASSIGNEE OF ENTIRE INTEREST  
AND REVOCATION OF PRIOR POWERS

The undersigned signatory (whose titled is supplied below) is empowered to act on behalf of the assignee identified below, and has reviewed all the documents in the chain of title of the patent application and, to the best of undersigned's knowledge and belief, title is in the assignee.

OKLAHOMA MEDICAL RESEARCH FOUNDATION

By: Lillian J. Thurman, Inc.  
Title: President

Date: 8/12/94